Cite

    Ramsauer, K. et al. (n.d.). Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet infectious diseases. 15 (5), pp. 519-527. [Online].